Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

• Published in: Blood Vol. 126; no. 23; p. 4230
• Main Authors: San Miguel, Jesús F, Hungria, Vânia TM, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Binlich, Florence, Richardson, Paul G.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 03.12.2015

Introduction: Panobinostat (PAN), a potent pan-deacetylase inhibitor, was the first agent of its class to produce a statistically significant and clinically meaningful increase in the median progression-free survival (PFS) of patients (pts) with relapsed or relapsed and refractory multiple myeloma (...